Randomized, double-blind, placebo-controlled, parallel-group, multicenter, Phase IIa trial to evaluate the efficacy and safety of AZD4831, over 12-24 weeks, in moderate to severe chronic obstructive pulmonary disease (COPD) (CRESCENDO)

CLINICAL TRIAL WITH MEDICINES